omeprazole sodium
Commercial- Indications
- Gastrointestinal disorders
Company intelligence / Profile preview
Nanjing Hicin has a diversified portfolio of approved and pipeline drugs. Landiolol hydrochloride targeting β1 adrenergic receptor for cardiac arrhythmias has been approved. The company also inlicensed a global IDH inhibitor program from Nerviano Medical Sciences for AML. Its product range covers antivirals, antibiotics, endocrine drugs and more; several APIs are exported internationally. The company maintains modern GMP-compliant manufacturing facilities and an active R&D center.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanjing Hicin Pharmaceutical Co., Ltd..